Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients.
We tested the security and efficacy of ezetimibe in the treatment of HIV-associated dyslipemia. Twenty HIV-infected patients were randomly assigned to receive ezetimibe 10 mg/day or fluvastatin 80 mg/day. Patients receiving ezetimibe experienced a statistically significant (P = 0.003) 20% reduction in the concentration of LDL-cholesterol, similar to that observed with fluvastatin (24%, P between groups 0.70). We concluded that ezetimibe monotherapy effectively decreases LDL-cholesterol in HIV-infected patients.
Coll
Blai
B
Centre de Recerca Biomédica, Reus, Spain.
Aragonés
Gerard
G
Parra
Sandra
S
Alonso-Villaverde
Carlos
C
Masana
Lluis
L
D000328:Adult; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods; D001384:Azetidines / Q000627:therapeutic use*; D002784:Cholesterol / Q000097:blood*; D008078:Cholesterol, LDL / Q000097:blood; D004727:Endothelium / Q000187:drug effects; D000069438:Ezetimibe; D005229:Fatty Acids, Monounsaturated / Q000627:therapeutic use; D000077340:Fluvastatin; D039682:HIV-Associated Lipodystrophy Syndrome / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D016896:Treatment Outcome
D000924:Anticholesteremic Agents; D001384:Azetidines; D008078:Cholesterol, LDL; D005229:Fatty Acids, Monounsaturated; D007211:Indoles; D000077340:Fluvastatin; D002784:Cholesterol; D000069438:Ezetimibe